EXEL Q1 2026 Earnings Call Summary

Exelixis Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Total Revenues: Approximately $611 million, driven by cabozantinib franchise net product revenues of $555 million.
CABOMETYX Revenue: Grew 8% year-over-year to $552.8 million, including $3.6 million from clinical trial sales.
Gross to Net Deductions: Increased to 30.2% due to higher 340B volume, Medicare Part D discounts, and co-pay assistance.
Operating Expenses: Approximately $359 million, a slight decrease from $363 million in Q4 2025.
Net Income: GAAP net income of $210.5 million ($0.81 per share) and non-GAAP net income of $232.8 million ($0.90 per share).
Cash and Marketable Securities: Approximately $1.4 billion.
Share Repurchase: $430.8 million of common stock repurchased, with a new $750 million repurchase plan authorized.

2. Strategic Updates and Business Highlights

CABOMETYX Performance: Continued strong growth, maintaining its position as the leading TKI for renal cell carcinoma (RCC) and neuroendocrine tumors (NETs).
ZANZA Development: NDA for ZANZA/atezolizumab combination in third-line plus colorectal cancer (CRC) under review, with a PDUFA date set for December 2026.
Pipeline Expansion: Seven pivotal trials for ZANZA ongoing or starting soon, including studies in RCC, CRC, prostate cancer, and neuroendocrine tumors.
Sales Team Expansion: Accelerated build-out of the GI sales team to enhance CABOMETYX market share and prepare for ZANZA's launch.

3. Forward Guidance and Outlook

Full Year 2026 Guidance: Reiterated, with expectations for continued growth in CABOMETYX and a successful launch of ZANZA in CRC.
Market Opportunity: The CRC market in the third-line plus setting is estimated at $1.5 billion, with significant potential for ZANZA.

4. Bad News, Challenges, or Points of Concern

Rising Gross to Net Deductions: Increased deductions may impact net revenues moving forward.
Event Accrual Delays: Slower event accrual in pivotal trials, particularly STELLAR-304, raises concerns about the timing of data readouts.
Competitive Landscape: Challenges in establishing ZANZA as a leading TKI in RCC due to complex treatment regimens and competition from other therapies.

5. Notable Q&A Insights

LITESPARK-012 Study: Discussion on the implications of the recent trial miss and its impact on future combination therapy strategies.
Market Dynamics: Insights into CABOMETYX's competitive position in RCC, with a focus on maintaining and growing market share amidst evolving treatment landscapes.
Regulatory Strategy: Emphasis on the importance of data from STELLAR-303 and its potential impact on the NDA submission for ZANZA.

Overall, Exelixis demonstrated strong financial performance in Q1 2026, with a focus on expanding its oncology portfolio and preparing for the potential launch of ZANZA. However, the company faces challenges related to market competition and trial dynamics that could impact future growth.

EXEL — Exelixis, Inc.